149 related articles for article (PubMed ID: 37005758)
21. Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway.
Wei C; Yao X; Jiang Z; Wang Y; Zhang D; Chen X; Fan X; Xie C; Cheng J; Fu J; Leung EL
Pharmacol Res; 2019 Jun; 144():79-89. PubMed ID: 30974169
[TBL] [Abstract][Full Text] [Related]
22. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
Song L; Coppola D; Livingston S; Cress D; Haura EB
Cancer Biol Ther; 2005 Mar; 4(3):267-76. PubMed ID: 15753661
[TBL] [Abstract][Full Text] [Related]
23. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L
Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).
Wang G; Reed E; Li QQ
Oncol Rep; 2004 Nov; 12(5):955-65. PubMed ID: 15492778
[TBL] [Abstract][Full Text] [Related]
25. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
26. Anticancer activity of methylene blue via inhibition of heat shock protein 70.
Sanchala D; Bhatt LK; Pethe P; Shelat R; Kulkarni YA
Biomed Pharmacother; 2018 Nov; 107():1037-1045. PubMed ID: 30257315
[TBL] [Abstract][Full Text] [Related]
27. 6-Shogaol Exhibits a Promoting Effect with Tax via Binding HSP60 in Non-Small-Cell Lung Cancer.
Mulati S; Jiang R; Wang J; Tao Y; Zhang W
Cells; 2022 Nov; 11(22):. PubMed ID: 36429106
[TBL] [Abstract][Full Text] [Related]
28. Ins and Outs of Heat Shock Proteins in Colorectal Carcinoma: Its Role in Carcinogenesis and Therapeutic Perspectives.
Abi Zamer B; El-Huneidi W; Eladl MA; Muhammad JS
Cells; 2021 Oct; 10(11):. PubMed ID: 34831085
[TBL] [Abstract][Full Text] [Related]
29. Targeting apoptosis by 1,2-diazole through regulation of EGFR, Bcl-2 and CDK-2 mediated signaling pathway in human non-small cell lung carcinoma A549 cells.
Vinod Prabhu V; Elangovan P; Niranjali Devaraj S; Sakthivel KM
Gene; 2018 Dec; 679():352-359. PubMed ID: 30218747
[TBL] [Abstract][Full Text] [Related]
30. Differential proteome and functional analysis of NSCLC cell lines in response to Tualang honey treatment.
Amran N; Abdul-Rahman PS
J Ethnopharmacol; 2022 Jul; 293():115264. PubMed ID: 35398242
[TBL] [Abstract][Full Text] [Related]
31. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
32. Interaction of FLNA and ANXA2 promotes gefitinib resistance by activating the Wnt pathway in non-small-cell lung cancer.
Cheng L; Tong Q
Mol Cell Biochem; 2021 Oct; 476(10):3563-3575. PubMed ID: 34018148
[TBL] [Abstract][Full Text] [Related]
33. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
34. GRP78, intronic polymorphisms, and pharmacogenomics in non-small cell lung cancer.
Merrick DT
Chest; 2012 Jun; 141(6):1377-1378. PubMed ID: 22670016
[No Abstract] [Full Text] [Related]
35. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
Elife; 2020 Sep; 9():. PubMed ID: 32897190
[TBL] [Abstract][Full Text] [Related]
36. Versatile Pt NCs-based chemotherapeutic agents significantly induce the apoptosis of cisplatin-resistant non-small cell lung cancer.
Xin Y; Huang X; Li Z; Zhao W; Wang C; Wang S; Yue X; Mo H; Li H
Biochem Biophys Res Commun; 2019 Apr; 512(2):218-223. PubMed ID: 30885437
[TBL] [Abstract][Full Text] [Related]
37. EGCG regulates the cross-talk between JWA and topoisomerase IIα in non-small-cell lung cancer (NSCLC) cells.
Li Y; Shen X; Wang X; Li A; Wang P; Jiang P; Zhou J; Feng Q
Sci Rep; 2015 Jun; 5():11009. PubMed ID: 26046674
[TBL] [Abstract][Full Text] [Related]
38. Intronic boundary mutation rs430397 cannot affect alternate splicing and is an indecisive risk factor for non-small cell lung cancer.
Zhu X; Fan W; Li D
Chest; 2012 Dec; 142(6):1691-1692. PubMed ID: 23208355
[No Abstract] [Full Text] [Related]
39. Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy.
Yun CW; Kim HJ; Lim JH; Lee SH
Cells; 2019 Dec; 9(1):. PubMed ID: 31878360
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
